Dakota Wealth Management Buys Shares of 5,921 Natera, Inc. $NTRA

Dakota Wealth Management bought a new stake in Natera, Inc. (NASDAQ:NTRA) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 5,921 shares of the medical research company’s stock, valued at approximately $1,356,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Connective Portfolio Management LLC acquired a new stake in shares of Natera during the 4th quarter worth approximately $779,000. DAVENPORT & Co LLC acquired a new position in Natera during the fourth quarter valued at approximately $3,215,000. E. Ohman J or Asset Management AB raised its position in Natera by 4.3% during the fourth quarter. E. Ohman J or Asset Management AB now owns 29,795 shares of the medical research company’s stock valued at $6,826,000 after purchasing an additional 1,232 shares in the last quarter. Systrade AG bought a new stake in Natera during the fourth quarter worth $11,454,000. Finally, True Wealth Design LLC lifted its stake in Natera by 12.2% during the fourth quarter. True Wealth Design LLC now owns 727 shares of the medical research company’s stock worth $167,000 after purchasing an additional 79 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

Insider Transactions at Natera

In other news, insider John Fesko sold 17,806 shares of the business’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $234.74, for a total transaction of $4,179,780.44. Following the sale, the insider directly owned 177,591 shares in the company, valued at approximately $41,687,711.34. The trade was a 9.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Steven Leonard Chapman sold 85,299 shares of the business’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $230.72, for a total value of $19,680,185.28. Following the sale, the chief executive officer owned 127,881 shares in the company, valued at approximately $29,504,704.32. This trade represents a 40.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 318,344 shares of company stock worth $74,091,416 in the last 90 days. 5.63% of the stock is currently owned by company insiders.

Natera Stock Performance

NASDAQ NTRA opened at $182.65 on Friday. The firm’s fifty day moving average price is $211.01 and its two-hundred day moving average price is $208.38. The stock has a market cap of $25.89 billion, a PE ratio of -119.38 and a beta of 1.65. Natera, Inc. has a fifty-two week low of $125.38 and a fifty-two week high of $256.36.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Thursday, February 26th. The medical research company reported $0.35 EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.81. Natera had a negative return on equity of 15.28% and a negative net margin of 9.03%.The company had revenue of $665.50 million during the quarter, compared to analysts’ expectations of $600.68 million. During the same period in the prior year, the company earned ($0.41) EPS. As a group, sell-side analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on NTRA shares. Wells Fargo & Company lifted their price target on Natera from $205.00 to $215.00 and gave the company an “equal weight” rating in a research note on Friday, February 27th. Morgan Stanley dropped their price objective on Natera from $265.00 to $250.00 and set an “overweight” rating for the company in a research report on Tuesday, March 3rd. JPMorgan Chase & Co. raised their price objective on Natera from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Robert W. Baird lifted their target price on Natera from $239.00 to $257.00 and gave the company an “outperform” rating in a research report on Friday, February 27th. Finally, Citigroup started coverage on Natera in a research note on Wednesday, January 7th. They set a “buy” rating and a $300.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $253.47.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.